
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.
| Revenue (TTM) | $4.14B |
| Gross Profit (TTM) | $1.38B |
| EBITDA | $615.50M |
| Operating Margin | 3.84% |
| Return on Equity | -48.70% |
| Return on Assets | 1.97% |
| Revenue/Share (TTM) | $29.83 |
| Book Value | $18.14 |
| Price-to-Book | 0.79 |
| Price-to-Sales (TTM) | 0.50 |
| EV/Revenue | 1.176 |
| EV/EBITDA | 10.21 |
| Quarterly Earnings Growth (YoY) | -63.60% |
| Quarterly Revenue Growth (YoY) | -3.20% |
| Shares Outstanding | $138.37M |
| Float | $138.08M |
| % Insiders | 0.40% |
| % Institutions | 120.65% |
Volatility is currently contracting

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to participate in investor meetings at the Barclays Global Consumer Conference on Thursday, September 10th, 2026. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe.

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two stocks is more attractive to value investors?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

I present my August top 5 dividend picks: PRGO, MZTI, NEE, TROW, and VICI, all rated Buy or Strong Buy for rising income and appreciation. Each pick trades at a significant discount to fair value (average 21.5%), offering an expected 5-year compound annual total return of ~12.5% and a 5.22% yield. PRGO, MZTI, and VICI stand out for deep undervaluation and robust dividend growth, with VICI offering a projected 15.8% CAGR and strong inflation-linked lease structures.

Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return.

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

PRGO tops Q2 EPS estimates as Infant Formula sales jump, helping offset softer demand and divestiture impacts while the company reaffirms 2026 guidance.

Perrigo Company plc (PRGO) Q2 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRGO and any ticker you trade — then tracks every position and per-strategy win rate.